For decades, patients whose small-cell lung cancer returned after initial treatment faced a narrow corridor of options and a prognosis measured in months. A randomized trial presented in September 2026 at the World Conference on Lung Cancer has widened that corridor: risvutatug rezetecan, an antibody-drug conjugate targeting the B7-H3 protein on cancer cells, nearly doubled median survival compared to the long-standing fallback chemotherapy topotecan. The findings place a new kind of hope in the hands of regulators and clinicians, and ultimately in the lives of patients for whom time has alway
Ris-Rez Shows 54% Survival Benefit Over Standard Treatment in Relapsed Lung Cancer
Patients with relapsed small-cell lung cancer, a highly aggressive cancer, now have access to a treatment that significantly extends median survival from 10.3 to 18.5 months.